HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 27/6/1183    most recent 09031936.06.00015605v1 Alert me when this article is cited Alert me if a correction is posted Permissions Request Permissions Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (5) Citing Articles via Google Scholar Google Scholar Articles by Huber, R. M. Articles by Steppling, H. Search for Related Content PubMed PubMed Citation Articles by Huber, R. M. Articles by Steppling, H.

Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell lung cancer

¹ Ludwig Maximilians University, Klinikum der Universität, Innenstadt, München, ² Dept of Pneumology and Thoracic Surgery, Krankenhaus Großhansdorf, Großhansdorf, ³ Dept of Internal Medicine, Robert Koch Klinik, Leipzig, ⁴ Asklepios Fachkliniken, Robert Koch Allee 2, Gauting, ⁵ Dept of Internal Medicine, St Vincentius Krankenhäuser, Karlsruhe, ⁶ Dept of Hematology and Oncology, St Franziskus Hospital, Flensburg, ⁷ Medical Dept, University of Bonn, Bonn, ⁸ Bezirksklinikum Obermain, Kutzenberg, Ebensfeld, ⁹ Dept of Internal Medicine II, Clemenshospital, Münster, Germany.

CORRESPONDENCE: R. M. Huber, Ludwig Maximilians Universität, Klinikum der Universität, Innenstadt, Ziemssenstrasse 1, 80336 München, Germany, Fax: 49 8951604905. E-mail: Huber{at}med.uni-munchen.de

Keywords: Second-line therapy, small cell lung cancer, topotecan

Received: February 10, 2005
Accepted January 29, 2006

The present prospective multicentre trial investigated whether topotecan, given at a starting dose of 1.25 mg·m^-2 with individual dose adjustment, can improve safety in patients with relapsed/refractory small cell lung cancer without loss of efficacy.

Patients received topotecan intravenously on days 1–5, every 21 days, for up to six courses. In the absence of relevant haematotoxicities, topotecan was increased to 1.5 mg·m^-2 and reduced to 1.0 mg·m^-2 in case of severe haematotoxicities.

Of 170 recruited patients, 73.2% had stage IV disease and 63.4% had platinum-containing pre-treatment. Patients received a total of 521 courses. In 72.6% of those courses, the dose remained at 1.25 mg·m^-2; in 9.1% it was reduced and in 18.3% it increased. Overall response rate was 14.1% including one complete response; 28.8% had stable disease. Median duration of response was 13.6 weeks and median survival was 23.4 weeks. Clinical benefit was obvious for sensitive as well as for refractory patients. Haematotoxicity of grade 3 or 4 was clearly lower compared with the standard dose of 1.5 mg·m^-2.

In conclusion, topotecan at a dose of 1.25 mg·m^-2 appears to be as effective as the dose of 1.5 mg·m^-2, but with reduced toxicity. Since patients with recurrent small cell lung cancer have a poor prognosis, they benefit especially from good tolerability.

This article has been cited by other articles:

				G A Silvestri and S G Spiro Carcinoma of the bronchus 60 years later Postgrad. Med. J., April 1, 2008; 84(990): 182 - 187. [Full Text] [PDF]

				M. O'Brien, J. Eckardt, and R. Ramlau Recent Advances with Topotecan in the Treatment of Lung Cancer Oncologist, October 1, 2007; 12(10): 1194 - 1204. [Abstract] [Full Text] [PDF]

				G A Silvestri and S G Spiro Carcinoma of the bronchus 60 years later. Thorax, December 1, 2006; 61(12): 1023 - 1028. [Full Text] [PDF]